14-day Premium Trial Subscription Try For FreeTry Free
Currently predicting for Mon, 6 May 2024

Trading levels for BCRX

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 4.76 7.04 %
R2 4.67 4.90 %
R1 4.61 3.57 %
Current price: 4.45
Support S1 4.42 -0.723 %
S2 4.36 -2.05 %
S3 4.26 -4.19 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 5.32 19.55 %
R2 5.14 15.51 %
R1 5.00 12.36 %
Current price 4.45
Support S1 4.43 -0.449%
S2 4.38 -1.57%
S3 4.16 -6.52%

BCRX Predictions History

3 years ago
Alan predicted that BCRX for 2020-11-30 is going $5.08 (-0.97%)

3 years ago
JS predicted that BCRX for 2020-07-13 is going $5.34 (7.88%)

3 years ago
JS predicted that BCRX for 2020-06-22 is going $3.71 (-4.63%)

3 years ago
HoI74 predicted that BCRX for 2020-06-22 is going

Rank:

3 years ago
JoshuaSlusin predicted that BCRX for 2020-06-11 is going $3.69 (-12.66%)

Rank:

3 years ago
JS predicted that BCRX for 2020-06-08 is going $3.98 (-9.55%)

3 years ago
HoI74 predicted that BCRX for 2020-06-08 is going $4.80 (15.11%)

Rank:

3 years ago
JS predicted that BCRX for 2020-06-01 is going $4.42 (-5.76%)

3 years ago
Desmond Lew predicted that BCRX for 2020-06-01 is going

Rank:

3 years ago
Forest.Balderson.96656 predicted that BCRX for 2020-06-01 is going

Rank:
Click to get the best stock tips daily for free!

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II... BCRX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT